Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 10;2020:5678210.
doi: 10.1155/2020/5678210. eCollection 2020.

Recurrent Gastrointestinal Hemorrhage in Children With Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated With Dasatinib: Case Reports

Affiliations
Free PMC article
Case Reports

Recurrent Gastrointestinal Hemorrhage in Children With Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated With Dasatinib: Case Reports

Xin Liao et al. Case Rep Hematol. .
Free PMC article

Abstract

Dasatinib, a second-line tyrosine kinase inhibitor (TKI), has been widely used in chronic myeloid leukemia (CML) and Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph + B-ALL). Although dasatinib has been well tolerated, side effects including hemorrhage are not rare. Cases of bleeding disorders ultimately result in thrombocytopenia, but platelet aggregation dysfunction induced by dasatinib has also been demonstrated in Ph + B-ALL and CML patients. We report three Chinese children with Ph + B-ALL who received a combination treatment of chemotherapy and dasatinib and developed gastrointestinal bleeding several months later. The platelet count and clotting tests were normal, and these patients presented with dasatinib-induced platelet dysfunction. These findings reveal that physicians should be aware of and carefully monitor for side effects, including bleeding disorders.

Conflict of interest statement

The authors report that they have no conflicts of interest.

Figures

Figure 1
Figure 1
PLT function tests of the three patients.
Figure 2
Figure 2
Endoscopy and biopsy results of the two patients.

Similar articles

See all similar articles

References

    1. Sun W., Malvar J., Sposto R., et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32(11):2316–2325. doi: 10.1038/s41375-018-0094-0. - DOI - PMC - PubMed
    1. Schultz K. R., Bowman W. P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. Journal of Clinical Oncology. 2009;27(31):5175–5181. doi: 10.1200/JCO.2008.21.2514. - DOI - PMC - PubMed
    1. Schultz K. R., Heerema N. A., Carroll A., et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–1471. doi: 10.1038/leu.2014.30. - DOI - PMC - PubMed
    1. Ravandi F., Jorgensen J. L., Thomas D. A., et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–1221. doi: 10.1182/blood-2012-11-466482. - DOI - PMC - PubMed
    1. Ravandi F., O’Brien S. M., Cortes J. E., et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–4164. doi: 10.1002/cncr.29646. - DOI - PMC - PubMed

Publication types

LinkOut - more resources

Feedback